1. Home
  2. GL vs ABVX Comparison

GL vs ABVX Comparison

Compare GL & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globe Life Inc.

GL

Globe Life Inc.

N/A

Current Price

$179.41

Market Cap

14.3B

Sector

Finance

ML Signal

N/A

Logo Abivax SA American

ABVX

Abivax SA American

N/A

Current Price

$120.73

Market Cap

11.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GL
ABVX
Founded
1900
2013
Country
United States
France
Employees
N/A
N/A
Industry
Life Insurance
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
14.3B
11.9B
IPO Year
1998
2022

Fundamental Metrics

Financial Performance
Metric
GL
ABVX
Price
$179.41
$120.73
Analyst Decision
Buy
Buy
Analyst Count
11
13
Target Price
$167.27
$131.31
AVG Volume (30 Days)
640.7K
829.0K
Earning Date
04-22-2026
03-23-2026
Dividend Yield
0.71%
N/A
EPS Growth
17.84
N/A
EPS
7.04
N/A
Revenue
$5,994,318,000.00
N/A
Revenue This Year
$9.64
$52.14
Revenue Next Year
$5.61
$4,132.27
P/E Ratio
$25.71
N/A
Revenue Growth
3.74
N/A
52 Week Low
$127.85
$67.15
52 Week High
$191.55
$148.83

Technical Indicators

Market Signals
Indicator
GL
ABVX
Relative Strength Index (RSI) 50.46 46.14
Support Level $174.84 $107.67
Resistance Level $182.32 $130.87
Average True Range (ATR) 3.58 4.74
MACD -0.72 -1.08
Stochastic Oscillator 23.85 28.87

Price Performance

Historical Comparison
GL
ABVX

About GL Globe Life Inc.

Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: